Minerva Neuroscience
Clinical-stage biotechnology company focused on development of therapeutics for central nervous system disorders. Activities described in source materials include preclinical research, small-molecule and recombinant-protein therapeutic development, multi-center randomized clinical trial design and execution, clinical outcome measurement and psychometric analysis, regulatory filings across jurisdictions, and licensing/royalty transactions.
Industries
Nr. of Employees
small (1-50)
Minerva Neuroscience
1500 District Avenue, Burlington, MA 01803, USA
Products
Roluperidone (MIN-101)
Small-molecule CNS compound with antagonist activity at 5-HT2A, sigma-2 and alpha-1 adrenergic receptors; developed to treat negative symptoms of schizophrenia and evaluated in randomized clinical trials.
MIN-301
Recombinant neuregulin-1β1 protein candidate in preclinical development for Parkinson’s disease with preclinical evidence of motor and cognitive improvement in disease models.
Seltorexant (previous co-development, royalty interest)
Orexin receptor antagonist program previously co-developed with a partner; the company retained and later sold royalty rights.
Roluperidone (MIN-101)
Small-molecule CNS compound with antagonist activity at 5-HT2A, sigma-2 and alpha-1 adrenergic receptors; developed to treat negative symptoms of schizophrenia and evaluated in randomized clinical trials.
MIN-301
Recombinant neuregulin-1β1 protein candidate in preclinical development for Parkinson’s disease with preclinical evidence of motor and cognitive improvement in disease models.
Seltorexant (previous co-development, royalty interest)
Orexin receptor antagonist program previously co-developed with a partner; the company retained and later sold royalty rights.
Expertise Areas
- CNS clinical trial management
- Clinical outcome measurement and psychometrics
- Neuropharmacology and receptor-targeted small-molecule development
- Recombinant protein therapeutic development
Key Technologies
- Mixed-effects models for repeated measures (MMRM)
- Confirmatory factor analysis and psychometric methods
- ANCOVA and Pearson correlation
- Effect size estimation
News & Updates
Phase 2b randomized controlled trial evaluating a non-dopaminergic small molecule for negative symptoms in schizophrenia; reported statistically significant improvements on primary and secondary endpoints.
Psychometric study reporting sensitivity of a negative symptom rating scale in a trial context.
Network-analysis reanalysis of clinical trial data indicating that changes in avolition-related items were central to treatment response.
Post-hoc analyses of Phase 2b trial data showing statistically significant improvements in reduced emotional experience and reduced emotional expression domains with effect-size estimates and time-course of separation from placebo.
Protocol-specified exploratory analysis reporting improvement on the Personal and Social Performance (PSP) final score (statistically significant for the higher dose) and domain-level changes; analyses included correlation and ANCOVA to assess independence from negative symptom scale changes.
Randomized, double-blind, placebo-controlled Phase 2b trial reported statistically significant improvements in negative symptoms versus placebo.
Phase 2b randomized controlled trial evaluating a non-dopaminergic small molecule for negative symptoms in schizophrenia; reported statistically significant improvements on primary and secondary endpoints.
Psychometric study reporting sensitivity of a negative symptom rating scale in a trial context.
Network-analysis reanalysis of clinical trial data indicating that changes in avolition-related items were central to treatment response.
Post-hoc analyses of Phase 2b trial data showing statistically significant improvements in reduced emotional experience and reduced emotional expression domains with effect-size estimates and time-course of separation from placebo.
Protocol-specified exploratory analysis reporting improvement on the Personal and Social Performance (PSP) final score (statistically significant for the higher dose) and domain-level changes; analyses included correlation and ANCOVA to assess independence from negative symptom scale changes.
Randomized, double-blind, placebo-controlled Phase 2b trial reported statistically significant improvements in negative symptoms versus placebo.